Get the latest updates in triple-negative breast cancer with these expert perspectives from our satellite symposium in Chicago. A variety of topics were discussed, including an overview of the molecular and clinical diversity of triple-negative breast cancer; the latest molecular, genetic, and immune-therapeutic targets for treatment; and a clinical practice update.
0.5 AMA PRA Category 1 Credits™
Jun 22, 2018
Jun 22, 2019
Sylvia Adams, MD, MSNew York University School of Medicine
Perlmutter Cancer Center
New York, New York, United States
Carsten Denkert, MDCharité University Hospital
Hope S. Rugo, MD, FASCOUniversity of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Nicholas Turner, MD, PhDRoyal Marsden Hospital
London, United Kingdom
Triple-negative breast cancer – Time to slice and dice?
Carsten Denkert, MD
Smart weapons in the treatment of triple-negative breast cancer
Hope S. Rugo, MD, FASCO
Exploiting abnormalities in DNA repair
Nicholas Turner, MD, PhD
Can we make immunotherapy a success in breast cancer?
Sylvia Adams, MD, MS
Hope S. Rugo, MD, FASCO
This educational activity is designed to meet the needs of medical oncologists, surgical and radiation oncologists, nurses, nurse practitioners, physician assistants, and other healthcare providers who treat and manage patients with breast cancer.
After successful completion of this educational activity, participants should be able to:
- Assess the molecular characteristics of triple-negative breast cancer and the clinical features of this diverse set of conditions
- Evaluate the results of recent clinical trials with novel targeted treatment approaches in triple-negative breast cancer
- Identify the relevance of PARPi in the treatment of patients with BRCA-mutated and BRCA-like triple-negative breast cancer
- Describe the potential role of immunotherapy in the management of triple-negative breast cancer
This educational activity is supported by grants from Merck and Co, Inc. and TESARO, Inc.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this live activity a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the post-test are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Adams has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Denkert has disclosed intellectual property rights and ownership interest with Sividon Diagnostics. He disclosed membership on an advisory committee or review panel with Amgen and MSD Oncology. He has received royalty from VMScope. He also disclosed that he has been a speaker or teacher for Amgen, Novartis, Roche, and TEVA. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Rugo has disclosed research support for clinical trials through the University of California from Amgen, Eisai, Genentech, Lilly, Macrogenics, Merck, Novartis, OBI, Pfizer, and Plexxikon. She also disclosed receipt of travel support from Amgen, Lilly, Merck, Mylan, Pfizer, and Puma. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Turner has disclosed that he has received consulting fees from AstraZeneca, Novartis, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – contracted research or research support from Amgen and Bayer
- Amy Furedy, RN, OCN, (scientific content reviewer/planner) –no relevant financial relationships
- Angela Zimmermann, PhD, (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) –no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.